Video

Kay Verble Discusses a Study to Characterize Long-Term Survivors of GBM

Author(s):

Kay Verble

Kay Verble discusses a research endeavor to characterize long-term survivors of glioblastoma multiforme (GBM).

Kay Verble, from the Sontag Foundation and Brain Tumor Network, discusses a research endeavor to characterize long-term survivors of glioblastoma multiforme (GBM).

Rick Sontag, one of our 2015 GBM Heroes, is an entrepreneur who has worked to improve the lives of patients with GBM and other brain tumors through a multifaceted approach to engaging and supporting the brightest scientific minds in brain cancer research.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.
Watch oncology dietitian Kenisha Parikh prepare creamy lentil soup, a soothing, protein-packed recipe to help ease side effects during treatment.
Related Content
Two patients treated with Temferon have lived three years post-surgery: © stock.adobe.com.
July 2nd 2025

Temferon Linked to Long-Term Survival in Some With Glioblastoma

Spencer Feldman
Two glioblastoma patients treated with Temferon have lived 3 years post-surgery; one had no progression, the other stabilized after initial progression.
Site Logo
August 29th 2019

Earning Your Legacy: Cancer Has Nothing To Do With It

Kristie L. Kahl
In this episode of the “CURE Talks Cancer” podcast, we spoke with Matt Newman, who was diagnosed with brain cancer at 39, but refuses to let cancer define the legacy he has made.
Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers: © stock.adobe.com.
June 20th 2025

Clinical Trial Corner: New Treatments in Leukemia, Lymphoma and Brain Cancers

Spencer Feldman
Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers, respectively, report early data showing safety/activity with novel therapies.
Site Logo
April 11th 2019

Addressing Nutritional Needs in Cancer

Kristie L. Kahl
In this week’s episode, we spoke with the founder and CEO of Savor Health on the importance of nutrition for patients and caregivers before, during and after cancer treatment.
The FDA granted fast track designation to RAD101 to improve detection of recurrent brain metastases: © stock.adobe.com.
June 13th 2025

FDA Grants Fast Track Designation to RAD101 in Brain Metastases

Spencer Feldman
The FDA granted fast track designation to RAD101, an experimental imaging agent, to improve detection of recurrent brain metastases.
Younger patients with grade 3 oligodendroglioma have fewer molecular abnormalities and longer survival than older patients: © stock.adobe.com.
May 19th 2025

Study Reveals Distinct Outcomes in Younger Patients With Grade 3 Oligodendroglioma

Spencer Feldman
Younger patients with grade 3 oligodendroglioma have fewer molecular abnormalities and longer survival than older patients, a study found.